AE-941 (Neovastat): a novel multifunctional antiangiogenic compound.

Laboratiore de médicine moléculaire Hôpital Ste-Justine-UQAM, Centre de cancérologie Charles-Bruneau, Centre de Recherche de l'Hôpital Ste-Justine, 3175, Chemin Côte-Ste-Catherine, Montréal, Québec H3T 1C5, Canada.
Expert Review of Anti-infective Therapy (Impact Factor: 2.07). 11/2001; 1(3):341-7. DOI: 10.1586/14737140.1.3.341
Source: PubMed

ABSTRACT AE-941 (Neovastat) is a naturally occurring product extracted from cartilage and has antiangiogenic properties. It has reached Phase III clinical trial evaluation for the treatment of solid tumors (non-small cell lung cancer and renal cell carcinoma) and a pivotal Phase II clinical trial in multiple myeloma is ongoing. AE-941 inhibits several steps of the angiogenesis process, including matrix metalloproteinase activities and VEGF signaling pathways. Moreover, AE-941 induces endothelial cell apoptosis and tissue-type plasminogen activator activity, thus suggesting that it is a multifunctional antiangiogenic drug. Results from Phase I/II clinical trials indicate that AE-941, given orally, is well tolerated. Moreover, the median survival time in patients with renal cell carcinoma and non-small cell lung cancer was significantly longer in patients receiving high doses of AE-941 compared to low doses.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Various pharmacological inhibitors of matrix metalloproteinases (MMPs) have been tested in phase I, II, and III trials of multiple cancer types and no significant evidence of efficacy has emerged. This overwhelming failure has understandably led to questions regarding MMPs as suitable drug targets in the oncology setting. In this chapter, a synopsis of the various trials and their results is presented along with a discussion of dose-limiting toxicities and the contrasting successful preclinical testing of these agents. Thoughtful application of the lessons learnt from the MMP inhibitor clinical experience should improve the likelihood of successful proteinase inhibitors in the future.
    12/2007: pages 759-785;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The search for an MMP inhibitor with anticancer efficacy is a nearly three-decade endeavor. This inhibitor is yet to be found. The reasons for this failure include shortcomings in the chemistry of these compounds (including broad MMP sub-type selectivity, metabolic lability, and toxicity) as well as the emerging, and arguably extraordinary, complexity of MMP cell (and cancer) biology. Together these suggest that the successful anticancer inhibitor must possess MMP selectivity against the MMP subtype whose involvement is critical, yet highly temporally (with respect to metastatic progression) and mechanistically (with respect to matrix degradation) regulated. This review summarizes the progression of chemical structure and mechanistic thinking toward these objectives, with emphasis on the disappointment, the perseverance, and the resilient optimism that such an inhibitor is there to be discovered.
    Cancer and metastasis reviews 04/2006; 25(1):115-36. · 7.79 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Multiple myeloma (MM) is an incurable plasma cell malignancy characterized by a monoclonal proliferation of plasma cells in the bone marrow (BM), secretion of paraprotein in serum, development of osteolytic bone lesions and an-giogenesis in the BM. In the BM, MM cells receive signals to survive and proliferate due to the existence of functional, mutual interactions between the MM cells and the BM stromal cells. This stroma not only offers protection against apop-tosis and leads to growth stimulation, but also has a role in the clinical very relevant drug resistance. As such, it became clear that the BM stroma can also become a therapeutical target in addition to the MM cells. In the past, the BM fibro-blasts were considered to be the main stromal cells that interact with the MM cells. However, since the observation of a myeloma associated angiogenesis in patients and in the 5TMM mouse model, it became clear that the endothelial cells (EC) are also an important participant of the BM stromal cells. BMEC are involved in the specific homing of MM cells and are a source of paracrine growth factors. In this review, the interaction between BMEC and MM cells will be dis-cussed.
    Current Immunology Reviews 01/2007; 300.